Zanladyne 8

Rx

Indications

• For the symptomatic treatment of mild to moderately Alzheimer’s dementia.

Dosage

Adults

• The starting dose is 4 mg twice daily for 4 weeks; if well-tolerated, the dose is then increased to 8 mg twice daily and maintained for at least 4 weeks.
• Subsequently, depending on the patient’s response and tolerability, the dose may be increased to 12 mg twice daily.
• If the patient shows no signs of improved response or does not tolerate the 24 mg/day dose, consider reducing the dose to 16 mg/day.
• Use with caution in patients with mild to moderate hepatic or renal impairment; the dose must not exceed 16 mg/day.
• For patients with moderate hepatic impairment: Start with 4 mg once daily for at least one week. Then, continue with 4 mg twice daily for at least 4 weeks. Do not exceed 16 mg/day.
• Do not use this medication in patients with hepatic impairment or in patients with renal impairment and a creatinine clearance of less than 9 mL/minute.

Administration

• Zanladyne 8 is administered orally, twice daily, preferably with breakfast and dinner. Ensure adequate fluid intake during treatment.

• Hypersensitivity to any ingredient of the drug.
• Patients who have both significant renal and hepatic impairment.
• Children.

Possible adverse reactions

• Nausea, vomiting, diarrhea,
• Loss of appetite,
• Weight loss,
• Adominal pain,
• Indigestion.

• The use of galantamine be discontinued at the first appearance of skin rash.
• Caution should be exercised when administering galantamine to patients with cardiovascular diseases.
• It should be considered when administering galantamine to patients with cerebrovascular disease, patients with a history of severe asthma or obstructive pulmonary disease or active pulmonary infections.
• The use of galantamine is not recommended in patients with urinary outflow obstruction or recovering from bladder surgery.
• Galantamine, as a cholinomimetic, is likely to exaggerate succinylcholine-type muscle relaxation during anaesthesia.
• Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucosegalactose malabsorption should not take this medicine.
• Caution should be exercised when prescribing to pregnant women.
• Women on galantamine should not breast-feed.
• Galantamine has minor to moderate influence on the ability to drive and use machines. Symptoms include dizziness and somnolence, especially during the first weeks after initiation of treatment.